• Search
  • Helpdesk
  • Sales contact

PRO

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

The primary aim of Phase 1 oncology clinical trials is to determine the safety of a new treatment, and to establish the Recommended Phase 2 Dose (RP2D), which is often...

Expanding investor confidence: The strategic value of Patient Reported Outcomes (PROs) in biotech fundraising

For biotech companies engaged in the clinical development of a therapeutic innovation, securing investor trust is as critical as demonstrating...

Leveraging the potential of Patient Reported Outcome (PRO) data to accelerate therapeutic innovation market access

Patients Reported Outcome (PRO) data provide information on patient health that is obtained directly from the patient.PRO measures serve to...

The critical importance of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies

In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....